SG10202104804PA - Methods and compositions for dosing in adoptive cell therapy - Google Patents
Methods and compositions for dosing in adoptive cell therapyInfo
- Publication number
- SG10202104804PA SG10202104804PA SG10202104804PA SG10202104804PA SG10202104804PA SG 10202104804P A SG10202104804P A SG 10202104804PA SG 10202104804P A SG10202104804P A SG 10202104804PA SG 10202104804P A SG10202104804P A SG 10202104804PA SG 10202104804P A SG10202104804P A SG 10202104804PA
- Authority
- SG
- Singapore
- Prior art keywords
- dosing
- compositions
- methods
- cell therapy
- adoptive cell
- Prior art date
Links
- 238000011467 adoptive cell therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/20—External fittings
- B65D25/205—Means for the attachment of labels, cards, coupons or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D77/00—Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
- B65D77/04—Articles or materials enclosed in two or more containers disposed one within another
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D77/00—Packages formed by enclosing articles or materials in preformed containers, e.g. boxes, cartons, sacks or bags
- B65D77/22—Details
- B65D77/24—Inserts or accessories added or incorporated during filling of containers
- B65D77/28—Cards, coupons, or drinking straws
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462066279P | 2014-10-20 | 2014-10-20 | |
US201562162647P | 2015-05-15 | 2015-05-15 | |
US201562168710P | 2015-05-29 | 2015-05-29 | |
US201562215732P | 2015-09-08 | 2015-09-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202104804PA true SG10202104804PA (en) | 2021-06-29 |
Family
ID=55761449
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202104804PA SG10202104804PA (en) | 2014-10-20 | 2015-10-20 | Methods and compositions for dosing in adoptive cell therapy |
SG11201703203RA SG11201703203RA (en) | 2014-10-20 | 2015-10-20 | Methods and compositions for dosing in adoptive cell therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703203RA SG11201703203RA (en) | 2014-10-20 | 2015-10-20 | Methods and compositions for dosing in adoptive cell therapy |
Country Status (13)
Country | Link |
---|---|
US (3) | US10507219B2 (es) |
EP (2) | EP3209690B1 (es) |
JP (3) | JP7057669B2 (es) |
KR (1) | KR20170068598A (es) |
CN (2) | CN107106610A (es) |
AU (1) | AU2015336029B2 (es) |
BR (1) | BR112017008042A2 (es) |
CA (1) | CA2964941A1 (es) |
ES (1) | ES2879612T3 (es) |
IL (2) | IL293714A (es) |
MX (2) | MX2017005106A (es) |
SG (2) | SG10202104804PA (es) |
WO (1) | WO2016064929A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL293714A (en) | 2014-10-20 | 2022-08-01 | Juno Therapeutics Inc | Methods and preparations for dosing in stress cell therapy |
US11266739B2 (en) | 2014-12-03 | 2022-03-08 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
US20210177896A1 (en) * | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
EP4011381A1 (en) | 2016-06-03 | 2022-06-15 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
KR20190034588A (ko) * | 2016-07-28 | 2019-04-02 | 노파르티스 아게 | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 |
WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP4353319A2 (en) | 2016-09-28 | 2024-04-17 | Atossa Therapeutics, Inc. | Methods of adoptive cell therapy |
CN109689686B (zh) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
AU2017368333A1 (en) * | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for determining CAR-T cells dosing |
KR20200010179A (ko) * | 2017-02-27 | 2020-01-30 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법에 있어서 투약과 관련된 조성물, 제조 물품 및 방법 |
EA201992155A1 (ru) | 2017-03-14 | 2020-03-16 | Джуно Терапьютикс, Инк. | Способы криогенного хранения |
CN111201438A (zh) | 2017-06-02 | 2020-05-26 | 朱诺治疗学股份有限公司 | 与和细胞疗法相关的毒性有关的制品和方法 |
CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
MA50057A (fr) * | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
US20200230221A1 (en) | 2017-09-19 | 2020-07-23 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
US10870703B2 (en) | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
US20210069246A1 (en) * | 2018-01-31 | 2021-03-11 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
EP3778649A4 (en) * | 2018-03-09 | 2022-05-04 | CRAGE medical Co., Limited | METHOD AND COMPOSITION FOR TREATMENT OF TUMOR |
CA3113618A1 (en) | 2018-09-28 | 2020-04-02 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
BR112021008263A2 (pt) * | 2018-10-31 | 2021-08-10 | Humanigen, Inc. | materiais e métodos para tratamento de câncer |
CA3134511A1 (en) * | 2019-03-22 | 2020-10-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
KR20220166282A (ko) | 2020-03-10 | 2022-12-16 | 매사추세츠 인스티튜트 오브 테크놀로지 | 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법 |
JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | NPM1c陽性がんの免疫療法のための組成物および方法 |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
AU2021305084A1 (en) | 2020-07-07 | 2023-02-02 | Cancure, Llc | MIC antibodies and binding agents and methods of using the same |
BR112023023269A2 (pt) * | 2021-05-11 | 2024-01-30 | Janssen Biotech Inc | Métodos de minimização de neurotoxicidade associada à terapia com células t do receptor de antígeno quimérico (car) |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
ES2766123T3 (es) | 2004-12-10 | 2020-06-11 | Peter Maccallum Cancer Inst | Métodos y composiciones para inmunoterapia adoptiva |
US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
EP2227334B1 (en) | 2007-12-07 | 2011-10-12 | Miltenyi Biotec GmbH | A centrifuge for separating a sample into at least two components |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
WO2010025177A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
EP2552959B1 (en) | 2010-03-26 | 2017-01-11 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
SG10201510092QA (en) | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
ES2535421T3 (es) * | 2011-03-22 | 2015-05-11 | Mucosis B.V. | Composiciones inmunogénicas en forma particulada y métodos para producir las mismas |
BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 a1―표적화된 t―세포 면역요법 |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
EP3824905A1 (en) | 2012-08-20 | 2021-05-26 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
EP2981607B1 (en) | 2013-04-03 | 2020-08-19 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
PL3129470T3 (pl) | 2014-04-07 | 2021-11-29 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
SG10201808825XA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Defined composition gene modified t-cell products |
ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
IL293714A (en) | 2014-10-20 | 2022-08-01 | Juno Therapeutics Inc | Methods and preparations for dosing in stress cell therapy |
PT3215601T (pt) | 2014-11-05 | 2020-08-03 | Juno Therapeutics Inc | Métodos de transdução e transformação de células |
US11266739B2 (en) | 2014-12-03 | 2022-03-08 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
MA41962A (fr) | 2015-04-23 | 2018-02-28 | Baylor College Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
EP3851110A1 (en) | 2015-05-28 | 2021-07-21 | Kite Pharma, Inc. | Methods of conditioning patients for t cell therapy |
WO2017096331A1 (en) | 2015-12-04 | 2017-06-08 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
MA43758A (fr) | 2016-03-16 | 2018-11-28 | Yuan Ji | Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés |
MA43759A (fr) | 2016-03-16 | 2018-11-28 | Jason Connor | Procédés de conception adaptative d'un régime de traitement et traitements associés |
ES2907557T3 (es) | 2016-03-22 | 2022-04-25 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Métodos de intervención temprana para prevenir o mejorar la toxicidad |
MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
AU2017368333A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for determining CAR-T cells dosing |
KR20200010179A (ko) | 2017-02-27 | 2020-01-30 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법에 있어서 투약과 관련된 조성물, 제조 물품 및 방법 |
CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
-
2015
- 2015-10-20 IL IL293714A patent/IL293714A/en unknown
- 2015-10-20 EP EP15793955.4A patent/EP3209690B1/en active Active
- 2015-10-20 US US14/918,451 patent/US10507219B2/en active Active
- 2015-10-20 SG SG10202104804PA patent/SG10202104804PA/en unknown
- 2015-10-20 SG SG11201703203RA patent/SG11201703203RA/en unknown
- 2015-10-20 WO PCT/US2015/056532 patent/WO2016064929A1/en active Application Filing
- 2015-10-20 ES ES15793955T patent/ES2879612T3/es active Active
- 2015-10-20 JP JP2017521100A patent/JP7057669B2/ja active Active
- 2015-10-20 CN CN201580069854.8A patent/CN107106610A/zh active Pending
- 2015-10-20 CN CN202310755252.4A patent/CN117427091A/zh active Pending
- 2015-10-20 BR BR112017008042A patent/BR112017008042A2/pt not_active Application Discontinuation
- 2015-10-20 IL IL251774A patent/IL251774B/en unknown
- 2015-10-20 MX MX2017005106A patent/MX2017005106A/es unknown
- 2015-10-20 CA CA2964941A patent/CA2964941A1/en active Pending
- 2015-10-20 AU AU2015336029A patent/AU2015336029B2/en active Active
- 2015-10-20 KR KR1020177013719A patent/KR20170068598A/ko not_active Application Discontinuation
- 2015-10-20 EP EP21171542.0A patent/EP3932950A1/en active Pending
-
2017
- 2017-04-19 MX MX2022006107A patent/MX2022006107A/es unknown
-
2019
- 2019-10-29 US US16/667,564 patent/US11633426B2/en active Active
-
2020
- 2020-11-13 JP JP2020189076A patent/JP2021035978A/ja active Pending
-
2022
- 2022-10-21 JP JP2022168766A patent/JP2023015098A/ja active Pending
-
2023
- 2023-03-22 US US18/188,380 patent/US20230285463A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10507219B2 (en) | 2019-12-17 |
IL251774A0 (en) | 2017-06-29 |
MX2017005106A (es) | 2017-07-05 |
US11633426B2 (en) | 2023-04-25 |
KR20170068598A (ko) | 2017-06-19 |
US20230285463A1 (en) | 2023-09-14 |
SG11201703203RA (en) | 2017-05-30 |
JP7057669B2 (ja) | 2022-04-20 |
AU2015336029B2 (en) | 2021-07-22 |
MX2022006107A (es) | 2022-06-14 |
EP3209690B1 (en) | 2021-05-05 |
JP2021035978A (ja) | 2021-03-04 |
IL251774B (en) | 2022-07-01 |
BR112017008042A2 (pt) | 2017-12-26 |
CA2964941A1 (en) | 2016-04-28 |
CN117427091A (zh) | 2024-01-23 |
US20160206656A1 (en) | 2016-07-21 |
EP3209690A1 (en) | 2017-08-30 |
AU2015336029A1 (en) | 2017-05-11 |
ES2879612T3 (es) | 2021-11-22 |
CN107106610A (zh) | 2017-08-29 |
JP2017533904A (ja) | 2017-11-16 |
EP3932950A1 (en) | 2022-01-05 |
IL293714A (en) | 2022-08-01 |
WO2016064929A1 (en) | 2016-04-28 |
JP2023015098A (ja) | 2023-01-31 |
US20200054680A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251774A0 (en) | Methods and preparations for dosing in stress cell therapy | |
HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
IL269440B (en) | Closed systems for use in the selection of immune cell populations for stress therapy | |
HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
IL259321A (en) | Preparations and methods for increasing gene expression in frogs | |
HK1245080A1 (zh) | 自然殺傷細胞的方法和組合物 | |
IL250072A0 (en) | Transgenic cells for stress cell therapy | |
IL251576A0 (en) | Methods and compositions for creating or maintaining multifunctional cells | |
HK1247957A1 (zh) | T細胞輸送治療分子的組合物和方法 | |
EP3215139A4 (en) | Compositions and methods for improved car-t cell therapies | |
HK1245834A1 (zh) | 一種b細胞用於體內遞送治療劑 | |
IL246607B (en) | Improved cellular preparations and methods for cancer treatment | |
SI3586821T1 (sl) | Sestavki in postopki za stimuliranje matičnih celic | |
PL3129057T3 (pl) | Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu | |
GB201500715D0 (en) | Improvements in and relating to zipwire trolleys | |
EP3164127A4 (en) | Compositions and methods to improve adoptive cell therapies | |
IL250178A0 (en) | Methods and preparations for the expression of peptides in the cell | |
SG11201702260RA (en) | Anti-cancer agent and cancer cell killing method | |
GB2520372B (en) | Improvements in and relating to heat-conducting apparatus | |
PL3191106T3 (pl) | Kompozycja zawierająca mikroalgę wzbogaconą w krzem do stosowania terapeutycznego | |
GB2530075B (en) | Improvements in and relating to eyewashing | |
GB201511158D0 (en) | Cell modification and application in therapy | |
GB201417432D0 (en) | Improvements in and relating to pipe-breaking | |
GB201409978D0 (en) | Novel compounds and their use in therapy | |
GB201412332D0 (en) | Improvements in and relating to polymer materials-ll |